全血细胞减少症
医学
肝脾肿大
酶替代疗法
基质还原疗法
骨量减少
骨痛
骨髓
病理
葡萄糖脑苷酶
疾病
儿科
胃肠病学
内科学
骨质疏松症
骨矿物
作者
Farid Alam,Jitendra Singh,Nilesh Kumar,Kailash Kumar,Anju Dinkar
出处
期刊:Cardiovascular and Hematological Disorders - Drug Targets
[Bentham Science]
日期:2023-06-01
卷期号:23 (2): 136-140
标识
DOI:10.2174/011871529x253966230922110202
摘要
Introduction: Gaucher's disease (GD) is a rare lysosomal storage disease. It is characterized by the deposition of glucocerebroside in cells of the macrophage-monocyte system. GD presents a broad clinical expression, including hematologic abnormalities (such as pancytopenia), massive hepatosplenomegaly, diffuse infiltrative pulmonary disease, renal involvement in the form of nephropathy and glomerulonephritis, skeletal involvement in the form of bone pain, bony infarct, osteopenia, and pathological fracture. Based on the presence or absence of neurologic involvement, it is differentiated into type 1, type 2, and type 3. Gaucher’s disease type 1 is the most common form, having the nonneuropathic form and carrying autosomal recessive traits. Gaucher's disease affects all racial and ethnic groups, while type 1 GD is most prevalent among Ashkenazi Jews. Case Presentation: A 20-year-old female was admitted to the medicine department with complaints of generalized weakness and easy fatigability, menorrhagia, and a dragging sensation in the abdomen. On clinical evaluation, she had bone marrow failure syndrome features along with massive splenomegaly. Later, she was confirmed with Gaucher disease type 1 disease by clinical and investigation (low β-glucosidase level) evaluation. Conclusion: This case emphasizes keeping a differential diagnosis of glycogen storage disorder while evaluating a case of unexplained pancytopenia with massive splenomegaly in adulthood for an extended period. Currently, enzyme replacement therapy and substrate reduction therapy are the mainstay therapeutic options for GD.
科研通智能强力驱动
Strongly Powered by AbleSci AI